Cardiome Pharma Corp. (COM) - Financial and Strategic SWOT Analysis Review

Date: June 7, 2016
Pages: 52
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C000587E0A9EN
Leaflet:

Download PDF Leaflet

Cardiome Pharma Corp. (COM) - Financial and Strategic SWOT Analysis Review
Cardiome Pharma Corp. (COM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Cardiome Pharma Corp. (Cardiome), pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company’s product portfolio includes two marketed productsfor the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults; and GP IIb/IIIa inhibitor used for the treatment of acute coronary syndrome. Its pipeline products also include vernakalant (oral), which is in phase II clinical trials. Cardiome has collaborations with other pharmaceutical companies to commercialize Brinavess. It has operational presence with offices located in Canada, the US, Switzerland and the UK. Cardiome is headquartered in Vancouver, British Columbia, Canada.

Cardiome Pharma Corp. Key Recent Developments

May 13, 2016: Cardiome Reports First Quarter 2016 Financial Results
Mar 10, 2016: Cardiome Reports Fourth Quarter and Full Year 2015 Financial Results
Feb 19, 2016: Cardiome announces filing of shelf prospectus and registration statement
Nov 13, 2015: Cardiome Reports Third Quarter 2015 Financial Results
Sep 08, 2015: Cardiome announces addition of Robert James Meyer, M.D. to board of directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Cardiome Pharma Corp. - Key Facts
Cardiome Pharma Corp. - Key Employees
Cardiome Pharma Corp. - Key Employee Biographies
Cardiome Pharma Corp. - Major Products and Services
Cardiome Pharma Corp. - Pharmaceutical Pipeline Products Data
Cardiome Pharma Corp., Pipeline Products by Therapy Area
Cardiome Pharma Corp., Pipeline Products by Development Phase
Cardiome Pharma Corp. - History
Cardiome Pharma Corp. - Company Statement
Cardiome Pharma Corp. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Cardiome Pharma Corp. - Business Description
Cardiome Pharma Corp. - Corporate Strategy
Cardiome Pharma Corp. - SWOT Analysis
SWOT Analysis - Overview
Cardiome Pharma Corp. - Strengths
Strength - Lead Product: Vernakalant
Strength - In-house Research Expertise
Cardiome Pharma Corp. - Weaknesses
Weakness - History of Operating Losses
Weakness - Decline in Europe Geographic segment
Cardiome Pharma Corp. - Opportunities
Opportunity - Potential Market: Atrial Fibrillation
Opportunity - Strategic Partnerships
Opportunity - Changing Demographics
Cardiome Pharma Corp. - Threats
Threat - Increasing Competitive Pressures
Threat - Government Regulations
Threat - Uncertain R&D Outcomes
Cardiome Pharma Corp. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Cardiome Pharma Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Cardiome Pharma Corp., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Cardiome Pharma Corp., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 13, 2016: Cardiome Reports First Quarter 2016 Financial Results
Mar 10, 2016: Cardiome Reports Fourth Quarter and Full Year 2015 Financial Results
Feb 19, 2016: Cardiome announces filing of shelf prospectus and registration statement
Nov 13, 2015: Cardiome Reports Third Quarter 2015 Financial Results
Sep 08, 2015: Cardiome announces addition of Robert James Meyer, M.D. to board of directors
Aug 05, 2015: Cardiome Reports Second Quarter 2015 Financial Results
Jun 12, 2015: Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation
Jun 03, 2015: Cardiome Appoints David Dean Vice President, Business Development and Investor Relations
May 13, 2015: Cardiome Reports First Quarter 2015 Financial Results
Mar 12, 2015: Cardiome reports fourth quarter and full year 2014 financial results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Cardiome Pharma Corp., Key Facts
Cardiome Pharma Corp., Key Employees
Cardiome Pharma Corp., Key Employee Biographies
Cardiome Pharma Corp., Major Products and Services
Cardiome Pharma Corp., Number of Pipeline Products by Therapy Area
Cardiome Pharma Corp., Number of Pipeline Products by Development Stage
Cardiome Pharma Corp., Pipeline Products By Therapy Area and Development Phase
Cardiome Pharma Corp., History
Cardiome Pharma Corp., Subsidiaries
Cardiome Pharma Corp., Key Competitors
Cardiome Pharma Corp., Ratios based on current share price
Cardiome Pharma Corp., Annual Ratios
Cardiome Pharma Corp., Interim Ratios
Cardiome Pharma Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Cardiome Pharma Corp., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Cardiome Pharma Corp., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Cardiome Pharma Corp., Pipeline Products by Therapy Area
Cardiome Pharma Corp., Pipeline Products by Development Phase
Cardiome Pharma Corp., Performance Chart (2011 - 2015)
Cardiome Pharma Corp., Ratio Charts
Cardiome Pharma Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Cardiome Pharma Corp., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Medtronic A/S
Chelsea Therapeutics International Ltd.
Celldex Therapeutics, Inc.
ASKA Research
Skip to top


Ask Your Question

Cardiome Pharma Corp. (COM) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: